Text Size

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

Gonzalez V.H., Berger B., Goldberg R., Gordon C.M., Khurana R.N., Angeles R., Shams N.


  • 2021
  • Translational vision science & technology
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Valley Retina Institute, TX, McAllen, United States; Retina Research Center, TX, Austin, United States; Bay Area Retina Associates, CA, United States; MI, Jackson, United States; Northern California Retina Vitreous Associates, Mountain View, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA; Santen USA, Emeryville, CA, USA; ProQR Therapeutics NV, MA, Cambridge, United States

Related Publications

Rapid and efficient generation of mature retinal organoids derived from human pluripotent stem cells via optimized pharmacological modulation of Sonic hedgehog, activin A, and retinoic acid signal transduction

Matsushita T.; Onishi A.; Matsuyama T.; Masuda T.; Ogino Y.; Kageyama M.; Takahashi M.; Uchiumi F.


Rotenone-Induced Optic Nerve Damage and Retinal Ganglion Cell Loss in Rats

Yamamoto Y.; Taniguchi T.; Shimazaki A.


Aging-associated changes of optical coherence tomography-measured ganglion cell-related retinal layer thickness and visual sensitivity in normal Japanese

Iwase A., Higashide T., Fujii M., Ohno Y., Tanaka Y., Kikawa T., Araie M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022